Sanofi-Aventis Acomplia (correction)
In a June 5 story on Sanofi-Aventis' incoming CEO Gerard Le Fur, "The Pink Sheet" incorrectly described the company's pending product Acomplia (rimonabant) as approved for weight loss. Acomplia was deemed "approvable" for weight loss and "not approvable" for smoking cessation in February (1"The Pink Sheet" Feb. 27, 2006, p. 4)...
You may also be interested in...
FDA is not requesting additional clinical trials for Acomplia's weight loss indication, Sanofi-Aventis said Feb. 24 during its investors meeting in Paris
Eye disease drugs have struggled to grow during the pandemic but Bayer's Regeneron-partnered blockbuster is going from strength to strength, helped by growth in Japan.
Amid the growing threat posed by variants of the coronavirus, the European Commission has published new rules allowing modified vaccines to be approved more quickly. The UK has identified one version of the B.1.167 virus variant as the most transmissible, although the jury is still out on its ability to evade vaccine protection.